Genomics and proteomics in renal cell carcinoma: Diagnosis, prognosis, and treatment selection

被引：4
|
作者：
Jones J. [1 ]
Pantuck A.J. [1 ]
机构：
[1] Department of Urology, David Geffen School of Medicine at UCLA, 66-118 Center for Health Sciences, Los Angeles
来源：
Current Urology Reports | 2008年 / 9卷 / 1期
关键词：
Renal Cell Carcinoma; Sorafenib; Sunitinib; Temsirolimus; Clear Cell Renal Cell Carcinoma;
D O I：
10.1007/s11934-008-0004-5
中图分类号：
学科分类号：
摘要：
The term renal cell carcinoma (RCC) once referred to a single entity but now encompasses a spectrum of diverse epithelial tumors with a common derivation from the renal tubular epithelium. The variable course of RCC remains problematic for patient management, despite advances in diagnosis and improved understanding of prognostic factors. However, powerful, high-throughput technologies that now analyze the entire genome and proteome promise to elucidate the heterogeneity of this disease and eventually enable a patient-tailored, individualized medicine. This review considers the clinical relevance and general significance of gene expression and protein-profiling studies. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码：9 / 14
页数：5
相关论文
共 50 条
  • [21] Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma
    Cheng, Guiyun
    Li, Mengru
    Ma, Xiaoyu
    Nan, Fangmei
    Zhang, Lu
    Yan, Zhongyi
    Li, Huimin
    Zhang, Guosen
    Han, Yali
    Xie, Longxiang
    Guo, Xiangqian
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [22] Sunitinib malate for the treatment of renal cell carcinoma
    Wood, Lori
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (09) : 1323 - 1336
  • [23] Tivozanib for the treatment of advanced renal cell carcinoma
    Chatzkel, Jonathan
    Ramnaraign, Brian
    Sonpavde, Guru
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (10) : 1135 - 1142
  • [24] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Porta, C.
    Schmidinger, M.
    Algaba, F.
    Patard, J. J.
    Khoo, V.
    Eisen, T.
    Horwich, A.
    ANNALS OF ONCOLOGY, 2014, 25 : 49 - 56
  • [25] A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma
    Patel, Hiren, V
    Srivastava, Arnav
    Srinivasan, Ramaprasad
    Singer, Eric A.
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (03) : 212 - 220
  • [26] Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis
    Razavinia, Amir
    Razavinia, Abazar
    Lou, Roya Jamshidi Khalife
    Ghavami, Mahlegha
    Shahri, Forouzan
    Tafazoli, Aida
    Khalesi, Bahman
    Hashemi, Zahra Sadat
    Khalili, Saeed
    HELIYON, 2024, 10 (12)
  • [27] New treatment approaches in renal cell carcinoma
    Facchini, Gaetano
    Perri, Francesco
    Caraglia, Michele
    Pisano, Carmela
    Striano, Stefano
    Marra, Luigi
    Fiore, Francesco
    Aprea, Pasquale
    Pignata, Sandro
    Iaffaioli, Rosario Vincenzo
    ANTI-CANCER DRUGS, 2009, 20 (10) : 893 - 900
  • [28] Optimizing treatment for metastatic renal cell carcinoma
    Patard, Jean-Jacques
    Porta, Camillo
    Wagstaff, John
    Gschwend, Juergen E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1901 - 1911
  • [29] Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma
    Kaptein, Fleur H. J.
    van der Hulle, Tom
    Braken, Sander J. E.
    Van Gennep, Erik J.
    Buijs, Jeroen T.
    Burgmans, Mark C.
    Cannegieter, Suzanne C.
    du Chatinier, Emma M. E.
    Huisman, Menno V.
    van Meerten, Els L. van Persijn
    Versteeg, Henri H.
    Pelger, Rob C. M.
    Klok, Frederikus A.
    JACC: CARDIOONCOLOGY, 2022, 4 (04): : 522 - 531
  • [30] MicroRNAs in Renal Cell Carcinoma: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy
    Al-Ali, Bader Mohamad
    Ress, Anna Lena
    Gerger, Armin
    Pichler, Martin
    ANTICANCER RESEARCH, 2012, 32 (09) : 3727 - 3732
12345